(i) the process must be responsive to stakeholders’ interests, in that the turn-around time for assessments must be minimized, transparency must be maximized, the process must be considered fair using universally agreed standards and the process must be modifiable based on stakeholders’ requirements, (ii) the assessment of medical technologies other than drugs may Selleck GS-7977 present different challenges and is managed separately in other HTA organizations, (m) because of the link between
HTA and reimbursement decisions, completion of the HTA process following regulatory approval can delay market access to new technologies,
thus closer integration between regulatory approval and HTA Selleckchem Emricasan processes is being explored internationally, (iv) there is a direct or indirect link to reimbursement in the jurisdictions explored – without this link the role of CER in the US will remain advisory; (v) each jurisdiction reviewed benefits from a single payer that is informed by the process – given the diverse multipayer environment in the US, CER in the US may usefully focus on generating comparative effectiveness evidence; (vi) a common metric for assessing intended and unintended effects of treatment allows comparison across different BAY 63-2521 molecular weight technologies, and (vii) one stated focus of CER is on therapeutic benefit among ‘high-priority populations’, including specific demographic groups (the elderly and children, racial and ethnic minorities) and individuals with disabilities, multiple chronic conditions and specific genomic factors. This will be difficult to achieve because epidemiological evidence of differences in therapeutic benefit among subgroups is detected
through effect modification, or more specifically, statistical evidence of effect measure modification, typically on relative measures of effect. Few randomized trials have enough power to detect effect modification and these have been uncommon in the scientific literature
As consideration is given to the development of a publicly funded CER body in the US, much can be learned from the international experience. Nevertheless, there are some distinctive features of the US healthcare system that must be taken into account when assessing the transferability of these insights”
“Background and Aim: Epidemiological studies have shown that increased serum uric acid (SUA) level is associated with coronary artery disease (CAD). Leukocytes have been shown to play an important role in the atherosclerotic process.